FGFR2 and cholangiocarcinoma: The same authors reported that TAS-120, an irreversible pan-FGFR inhibitor, was effective in 4 patients with FGFR2 fusion-positive CCA who developed resistance to previous FGFR inhibition and were selected through examination of serial biopsies, ctDNA, and patient-derived tumor cells [40] (Table 2).